Antivirotika pro systémové použití COVID - 19 I. - Remdesivir
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| 23654439 | 02. 08. 2023 | Gilead Sciences s.r.o. | 32 172 800,00 | 29 248 000,00 | 32 172 800,00 | 29 248 000,00 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| 392_Písemná zpráva_podepsano.pdf | Písemná zpráva zadavatele | 12. 09. 2023 15:15 | Dokument není zavirovaný |
List of Participants
| Show detail | |||||||
|---|---|---|---|---|---|---|---|
| Gilead Sciences s.r.o. | Praha | 29 247 996,00 | CZK |
Price Actually Paid in Each Year of Performance
| 23654439 | 2023 | 2 060 924,00 | 1 873 567,28 |